BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 38130152)

  • 1. Commentary: Nanoparticle-Based Chemotherapy Delivery and Potential Health Risks: Prospects for Effective Clinical Translation.
    Assefa D; Melaku T; Alemu S
    Technol Cancer Res Treat; 2023; 22():15330338231220171. PubMed ID: 38130152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
    Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
    Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug delivery and nanoparticles:applications and hazards.
    De Jong WH; Borm PJ
    Int J Nanomedicine; 2008; 3(2):133-49. PubMed ID: 18686775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticle-Induced Complement Activation: Implications for Cancer Nanomedicine.
    La-Beck NM; Islam MR; Markiewski MM
    Front Immunol; 2020; 11():603039. PubMed ID: 33488603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoparticle-assisted combination therapies for effective cancer treatment.
    Hu CM; Aryal S; Zhang L
    Ther Deliv; 2010 Aug; 1(2):323-34. PubMed ID: 22816135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating Therapeutic Ultrasound With Nanosized Drug Delivery Systems in the Battle Against Cancer.
    Moradi Kashkooli ; Jakhmola A; Ferrier GA; Hornsby TK; Tavakkoli JJ; Kolios MC
    Technol Cancer Res Treat; 2023; 22():15330338231211472. PubMed ID: 37946517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation effects on the tumor microenvironment: Implications for nanomedicine delivery.
    Stapleton S; Jaffray D; Milosevic M
    Adv Drug Deliv Rev; 2017 Jan; 109():119-130. PubMed ID: 27262923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoscale drug delivery for targeted chemotherapy.
    Xin Y; Huang Q; Tang JQ; Hou XY; Zhang P; Zhang LZ; Jiang G
    Cancer Lett; 2016 Aug; 379(1):24-31. PubMed ID: 27235607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming obstacles in the tumor microenvironment: Recent advancements in nanoparticle delivery for cancer theranostics.
    Overchuk M; Zheng G
    Biomaterials; 2018 Feb; 156():217-237. PubMed ID: 29207323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor microenvironment and nanotherapeutics: intruding the tumor fort.
    Ravi Kiran AVVV; Kusuma Kumari G; Krishnamurthy PT; Khaydarov RR
    Biomater Sci; 2021 Nov; 9(23):7667-7704. PubMed ID: 34673853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation.
    Taha MS; Padmakumar S; Singh A; Amiji MM
    Drug Deliv Transl Res; 2020 Jun; 10(3):766-790. PubMed ID: 32170656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organoids technology for advancing the clinical translation of cancer nanomedicine.
    Zhao DK; Liang J; Huang XY; Shen S; Wang J
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(5):e1892. PubMed ID: 37088100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor heterogeneity and nanoparticle-mediated tumor targeting: the importance of delivery system personalization.
    Swetha KL; Roy A
    Drug Deliv Transl Res; 2018 Oct; 8(5):1508-1526. PubMed ID: 30128797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined cancer therapeutics-Tackling the complexity of the tumor microenvironment.
    Roma-Rodrigues C; Raposo LR; Valente R; Fernandes AR; Baptista PV
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Sep; 13(5):e1704. PubMed ID: 33565269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy.
    Moosavian SA; Bianconi V; Pirro M; Sahebkar A
    Semin Cancer Biol; 2021 Feb; 69():337-348. PubMed ID: 31585213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spatial heterogeneity of nanomedicine investigated by multiscale imaging of the drug, the nanoparticle and the tumour environment.
    de Maar JS; Sofias AM; Porta Siegel T; Vreeken RJ; Moonen C; Bos C; Deckers R
    Theranostics; 2020; 10(4):1884-1909. PubMed ID: 32042343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chloroquine and nanoparticle drug delivery: A promising combination.
    Pelt J; Busatto S; Ferrari M; Thompson EA; Mody K; Wolfram J
    Pharmacol Ther; 2018 Nov; 191():43-49. PubMed ID: 29932886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In situ cellular hitchhiking of nanoparticles for drug delivery.
    Udofa E; Zhao Z
    Adv Drug Deliv Rev; 2024 Jan; 204():115143. PubMed ID: 38008185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Responsive Role of Nanomedicine in the Tumor Microenvironment and Cancer Drug Resistance.
    Sa P; Sahoo SK; Dilnawaz F
    Curr Med Chem; 2023; 30(29):3335-3355. PubMed ID: 36154585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.